Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BFRI 
Biofrontera Inc (BFRI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BFRI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -76.01% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.29M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 2 | Beta 0.5 | 52 Weeks Range 0.54 - 1.38 | Updated Date 09/17/2025 |
52 Weeks Range 0.54 - 1.38 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -42.34% | Operating Margin (TTM) -56.25% |
Management Effectiveness
Return on Assets (TTM) -48.85% | Return on Equity (TTM) -531.54% |
Valuation
Trailing PE - | Forward PE 10.88 | Enterprise Value 7046079 | Price to Sales(TTM) 0.24 |
Enterprise Value 7046079 | Price to Sales(TTM) 0.24 | ||
Enterprise Value to Revenue 0.18 | Enterprise Value to EBITDA -0.79 | Shares Outstanding 10668400 | Shares Floating 8482051 |
Shares Outstanding 10668400 | Shares Floating 8482051 | ||
Percent Insiders 12.74 | Percent Institutions 21.92 |
Upturn AI SWOT
Biofrontera Inc
Company Overview
History and Background
Biofrontera Inc., was established to commercialize dermatological products. Originally Biofrontera AG, the company focuses on the development and sale of pharmaceutical drugs and medical cosmetics for the treatment and prevention of skin diseases. The company has primarily focused on the treatment of actinic keratoses.
Core Business Areas
- Prescription Drugs: Development and commercialization of prescription drugs for the treatment of dermatological conditions, primarily actinic keratosis.
- Medical Cosmetics: Development and commercialization of medical cosmetic products.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical and dermatology sectors. The organizational structure is typical for a publicly traded pharmaceutical company, with departments for R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Ameluz: A topical prescription drug used in combination with photodynamic therapy (PDT) for the treatment of actinic keratoses of mild to moderate severity on the face and scalp. Market share data varies, but Biofrontera aims to compete with existing treatments like Efudex and Picato. Competing products include: Blue light devices (standalone), Solaraze, Zyclara.
Market Dynamics
Industry Overview
The dermatology market is experiencing growth driven by an aging population and increased awareness of skin conditions. There is increasing demand for non-invasive and effective treatments.
Positioning
Biofrontera Inc. aims to be a leading provider of PDT-based treatments for actinic keratosis. Their competitive advantage lies in their Ameluz product and its efficacy when used with PDT.
Total Addressable Market (TAM)
The TAM for actinic keratosis treatment is significant. Ameluz positioned to capture a reasonable share of this market. Accurate TAM figures in the billions.
Upturn SWOT Analysis
Strengths
- Proprietary Ameluz formulation
- Established PDT treatment process
- Focus on a specific dermatological niche
Weaknesses
- Reliance on a single key product (Ameluz)
- Relatively small market capitalization
- Dependence on reimbursement policies
Opportunities
- Expansion into new geographic markets
- Development of new dermatological products
- Partnerships with dermatology clinics and practices
Threats
- Competition from established pharmaceutical companies
- Changes in reimbursement policies
- Potential for generic competition
Competitors and Market Share
Key Competitors
- LEO Pharma (no public US ticker)
- Galderma (no public US ticker)
- Sun Pharmaceutical (SUNPHARMA.NS)
Competitive Landscape
Biofrontera Inc. competes with larger pharmaceutical companies with established dermatology portfolios. Their advantage lies in their specific focus on PDT-based treatments. Their disadvantage is their relatively smaller size and resources.
Growth Trajectory and Initiatives
Historical Growth: Biofrontera has experienced moderate growth in revenue driven by sales of Ameluz. However, profitability has been a challenge.
Future Projections: Future growth will depend on the success of Ameluz in existing markets, expansion into new markets, and the development of new products. Analyst estimates are available on financial websites.
Recent Initiatives: Recent strategic initiatives include efforts to increase sales of Ameluz, expand into new markets, and potentially develop new products or formulations.
Summary
Biofrontera Inc. is a small but focused company in the dermatology market, primarily reliant on its Ameluz product. While it shows promise with PDT treatments, it faces stiff competition and financial challenges typical of growth-stage pharmaceutical firms. Expanding its product line and securing better reimbursement policies will be crucial for its long-term success. Investors should be aware of the risks associated with a small-cap pharmaceutical company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Biofrontera Inc. Investor Relations
- Third-party financial analysis websites
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own due diligence and risk tolerance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biofrontera Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 92 | Website https://www.biofrontera-us.com |
Full time employees 92 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.